· ST-SPC-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across this corpus, patients with chronic kidney disease who took statins or had more intensive cholesterol lowering tended to have fewer heart attacks, strokes and related cardiovascular events. The clearest head-to-head signal comes from a study comparing statin users with non-users, which found progressively fewer events as the statin dose rose [2]. Other studies point the same direction: one statin outperformed another on cardiovascular events [1], adding a second lipid-lowering drug helped more as kidney function fell [13], and higher cholesterol tracked with higher cardiovascular risk in CKD [3]. The main weakness is that the one placebo-controlled trial in this corpus [4] reports only cholesterol results, not cardiovascular event results, so the strongest direct evidence here is observational rather than from a randomised trial. There is also a signal that the benefit may fade in people on dialysis or with end-stage disease [3]. The panel treated the consistent direction as real support while noting these gaps hold it short of the top tier.
The one direct statin-versus-non-use comparison in CKD shows statin therapy independently associated with lower MACE, with a dose-response across nonuser, low-to-moderate and high-dose groups [2]. A large target-trial-emulation cohort shows a within-statin cardiovascular difference, with lower MACE risk for one statin over another [1]. A post-hoc analysis shows intensified lipid-lowering yielding greater cardiovascular benefit as eGFR declines [13], and a population cohort establishes that higher LDL-C tracks with higher cardiovascular risk in CKD [3]. Together these span distinct populations and point consistently toward fewer cardiovascular events with statin or lipid-lowering exposure in CKD. The only placebo-controlled randomised trial [4] contributes LDL-C lowering but no cardiovascular event result in this corpus. The contested point: The evidence divides on how directly it supports statins specifically: the cleanest randomised design [4] reports no cardiovascular outcomes, the strongest direct result [2] is a single-centre retrospective case-control, and two supporting papers [4][13] test ezetimibe-plus-simvastatin rather than a statin alone. It also divides on scope, since the LDL-C to cardiovascular association seen in CKD was not observed in the end-stage group [3].
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The landmark placebo-controlled RCT in CKD (SHARP) appears only as its design/baseline paper [4], which reports LDL-C lowering and explicitly no cardiovascular outcomes ('Follow-up is scheduled to continue until August 2010'). The corpus contains no statin-vs-placebo RCT with reported CV event results.
The most direct statin-vs-non-use CV-outcome evidence [2] is a single-centre retrospective case-control (N=765) in a narrow CKD+cardiomyopathy population, vulnerable to confounding by indication despite covariate adjustment.
Where it remains uncertain. The one placebo-controlled trial [4] reports only LDL-C lowering with no cardiovascular outcome, and the LDL-C to cardiovascular link in CKD was not observed in end-stage disease [3].
Aleatory
The direct statin-vs-non-use result rests on 765 patients (255 cases, 510 controls) in a single CKD-plus-cardiomyopathy centre [2], leaving outcome counts sparse and chance-sensitive.
Epistemic
The only placebo-controlled trial [4] reports LDL-C lowering but no cardiovascular event result in this corpus, so the randomised test of the claim is unresolved here.
Inferential
The direct result [2] is retrospective case-control, so who received statins may differ systematically from who did not despite covariate adjustment.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Within-statin comparison in diabetes across CKD stages; CV benefit differs by statin but both arms treated (indirect support).
“accounting for time-varying exposure revealed a lower risk of MACE (HR = 0.85 [0.77-0.93]) and all-cause mortality (HR = 0.88 [0.81-0.96]) with rosuvastatin”
Panel auditInternal validity: medium · scope of inference: East Asian (Hong Kong Chinese) patients with diabetes across CKD stages G1-4, comparing two statins' cardiorenal outcomes.Key limitations: no statin-free comparator · observational/confounding · diabetes-only population · East Asian only
Direct statin-vs-nonuse evidence of reduced MACE in CKD patients, with dose-response.
“the incidence of MACE decreased progressively across nonuser, low-to-moderate, and high-dose groups (41.1% vs 28.7% vs 20.2%, P for trend = .002)”
Panel auditInternal validity: low · scope of inference: Hospitalised patients with CKD complicated by cardiomyopathy across CKD stages and cardiomyopathy etiologies.Key limitations: retrospective case-control · single centre · confounding by indication · CKD-with-cardiomyopathy subgroup only
Establishes LDL-C to CV-event causal rationale in CKD; also flags attenuation at ESKD.
“In the chronic kidney disease group, LDL-C levels ≥ 100 mg/dL were significantly associated with increased composite cardiovascular event risk compared with < 70 mg/dL; however, this adjusted association was not observed in the end-stage kidney disease group”
Panel auditInternal validity: medium · scope of inference: Korean adults without prior cardiovascular disease, examining LDL-C thresholds and cardiovascular risk by CKD stage.Key limitations: not a statin-treatment study · observational association · no intervention tested
The abstract reports LDL differences and absence of early toxicity only; the key cardiovascular outcome results are not yet reported in this design paper.
Panel auditInternal validity: high · scope of inference: Patients with advanced CKD (including 3,056 on dialysis) without prior MI or coronary revascularisation; intervention is a statin plus ezetimibe, not statin alone.Key limitations: no outcome results in abstract · intervention is statin + ezetimibe combination · design/rationale paper only
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A consistent directional signal across independent observational and comparative datasets supports the claim, but the absence of RCT CV-outcome results and reliance on observational and combination-therapy data cap confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised CV-outcome statin trial in CKD. Without a placebo-controlled statin trial reporting cardiovascular events, the claim's direct support in this corpus rests on observational data [2]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Report the cardiovascular event results of a placebo-controlled statin trial enrolling CKD patients, as [4] was designed to provide.
Open question: Do statins reduce hard cardiovascular events versus placebo in CKD when tested in a randomised trial reporting outcomes? Why it is still open: The one placebo-controlled trial in the corpus [4] reports only LDL-C lowering and no cardiovascular event result.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19